Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A

Rosemarie Schobess; Karin Kurnik; Frauke Friedrichs; Susan Halimeh; Anne Krümpel; Christoph Bidlingmaier; Ulrike Nowak-Göttl

doi:10.1160/TH07-06-0417

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(01): 71-76
DOI: 10.1160/TH07-06-0417

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A

Rosemarie Schobess

¹Department of Pediatrics, University Hospital Halle, Halle, Germany

,

Karin Kurnik

²Department of Pediatrics, University Hospital Munich, Munich, Germany

,

Frauke Friedrichs

³Leibniz-Institute for Arteriosclerosis Research, University of Muenster, Muenster, Germany

,

Susan Halimeh

⁴Department of Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany

,

Anne Krümpel

⁴Department of Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany

,

Christoph Bidlingmaier

²Department of Pediatrics, University Hospital Munich, Munich, Germany

,

Ulrike Nowak-Göttl

⁴Department of Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany

› Author Affiliations

Abstract

Full Text

PDF Download

Keywords

Severe haemophilia A - on-demand - primary prophylaxis - joint damage

References

References
1 Nilsson IM, Berntorp E, Löfqvist T. et al. Twentyfive years’ experience of prophylactic treatment in severe hemophilia A and B. J Intern Med 1992; 232: 25-32.
2 Astermark J, Petrini P, Tengborn L. et al. Primary prophylaxis in severe hemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-1113.
3 Fischer K, van der Bom JG, Mauser-Bunschoten EP. et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-452.
4 Ljung R. Paediatric care of the child with haemophilia. Haemophilia 2002; 8: 178-182.
5 Blanchette VS, Manco-Johnson M, Santagostino E. et al. Optimizing factor prophylaxis for the haemophilia population: where do we stand?. Haemophilia 2004; 10/4: 97-104.
6 Fischer K, van der Bom JG. Molho et al. Prophylactic versus on-demand treatment strategies for severe hemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-752.
7 Carlsson KS, Höjgard S, Glomstein A. et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-566.
8 Kern M, Blanchette V, Stain AM. et al. Clinical and cost implications of target joints in Canadian boys with severe hemophilia. J Pediatr 2004; 145: 628-634.
9 Rahi JS, Manaras I, Tuomainen H. et al. Meeting the needs of parents around the time of diagnosis of disability among their children: evaluation of a novel program for information, support, and liaison by key workers. Pediatrics 2004; 114: e482.
10 Berntorp E, Astermark J, Björkman S. et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9: 1-4.
11 Ota S, Mclimont M, Carcao MD. et al. Definitions for haemophilia prophylaxis and its outcomes: The Canadian Consensus Study. Haemophilia 2007; 13: 12-20.
12 Nuss R, Kilcoyne RF, Geraghty S. et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000; 6: 162-169.
13 Thomas DC, Greenland S. The relative efficiencies of matched and independent sample designs for casecontrol studies. J Chron Dis 1983; 36: 685-697.
14 Kreuz W, Escuriola Ettingshausen C. et al. Prevention of joint damage in hemophiliac children with early prophylaxis. Orthopäde 1999; 28: 341-346.
15 Kreuz W, Escuriola-Ettingshausen C, Funk M. et al. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-417.
16 Mayer D. Essential evidence-based Medicine.. Cambridge University Press; : 2004: 58-60.
17 Pettersson H, Nilsson IM, Hedner U. et al. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paed Scand 1981; 70: 565-570.
18 Bogdanova N, Markoff A, Pollmann H. et al. Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A. Hum Mutat 2005; 26: 249-254.
19 Escuriola Ettingshausen C, Halimeh S, Kurnik K. et al. Hemophilia phenotype is dependent on the presence of prothrombotic risk factors. A multicenter cohort study. Thromb Haemost 2001; 85: 218-220.
20 Gouw SC, van der Bom JG, van den Berg HM. et al. Treatment related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
21 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-544.
22 Fischer K, Astermark J, van der Bom JG. et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-760.
23 Van den Berg HM, Fischer K, Mauser-Bunschoten EP. et al. Long-term outcome in individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-565.
24 Fischer K, van der Bom JG, Mauser-Bunschoten EP. et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-2341.